Skip to main navigation Skip to search Skip to main content

Erratum: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: A multicenter randomized controlled parallel group trial (TiMiSNAR) (BMC Cancer (2019) 19 (1215) DOI: 10.1186/s12885-019-6271-3)

  • Igor Monsellato
  • , Filippo Alongi
  • , Elisa Bertocchi
  • , Stefania Gori
  • , Giacomo Ruffo
  • , Elisa Cassinotti
  • , Ludovica Baldari
  • , Luigi Boni
  • , Graziano Pernazza
  • , Fabio Pulighe
  • , Carlo De Nisco
  • , Roberto Perinotti
  • , Emilio Morpurgo
  • , Tania Contardo
  • , Enzo Mammano
  • , Ugo Elmore
  • , Roberto Delpini
  • , Riccardo Rosati
  • , Federico Perna
  • , Andrea Coratti
  • Benedetta Menegatti, Sergio Gentilli, Paolo Baroffio, Piero Buccianti, Riccardo Balestri, Cristina Ceccarelli, Valter Torri, Davide Cavaliere, Leonardo Solaini, Giorgio Ercolani, Elena Traverso, Vittorio Fusco, Maura Rossi, Fabio Priora, G. Numico, Paola Franzone, Sara Orecchia

Research output: Contribution to journalComment/debate

Abstract

Following publication of the original article [1], the authors reported that the family name of the author, Ludovica Baldari, was misspelled. Incorrect: Ludovica Baldarti Correct: Ludovica Baldari.

Original languageEnglish
Article number128
JournalBMC Cancer
Volume20
Issue number1
DOIs
Publication statusPublished - 17 Feb 2020
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Erratum: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: A multicenter randomized controlled parallel group trial (TiMiSNAR) (BMC Cancer (2019) 19 (1215) DOI: 10.1186/s12885-019-6271-3)'. Together they form a unique fingerprint.

Cite this